Simultaneous treatment with carbimazole and granulocyte-colony stimulating factor in a patient with thyrotoxicosis and carbimazole induced neutropenia

• Authors: Indrajit Talapatra , Vengal Nagareddy , Manju Bhavnani , David Tymms
• Languages of publication: EN

Abstracts

EN

We describe a patient who was admitted with uncontrolled thyrotoxicosis and carbimazole induced neutropenia. She required 80 mg of carbimazole daily. The patient declined radio-iodine treatment because she had a little child and wished to have thyroid surgery. She received four doses of filgrastim (Granulocyte-colony stimulating factor) which maintained the neutrophil count within a reasonable level while she continued to receive carbimazole to prepare her for surgery. After a curative subtotal thyroidectomy and discontinuation of the carbimazole, the patient’s white cell count remained normal. Subsequently the patient was euthyroid on levothyroxine replacement. Carbimazole should always be discontinued if neutropenia occurs but this case demonstrates that in exceptional circumstances filgrastim can be an effective therapy while continuing carbimazole in the short term.

Keywords

EN

Neutropenia; thyrotoxicosis; granulocyte-colony stimulating factor

• Publisher: De Gruyter Open
• Journal: Open Medicine
• Year: 2006
• Volume: 1
• Issue: 4
• Pages: 419-423

Dates

published

1 - 12 - 2006

online

24 - 10 - 2006

Contributors

author

Indrajit Talapatra

• Royal Albert Edward Infirmary, Wigan, WN1 2NN, UK

author

Vengal Nagareddy

• Royal Albert Edward Infirmary, Wigan, WN1 2NN, UK

author

Manju Bhavnani

• Royal Albert Edward Infirmary, Wigan, WN1 2NN, UK

author

David Tymms

• Royal Albert Edward Infirmary, Wigan, WN1 2NN, UK

References

• [1] N. Biswas, A. You-hern, J.M. Goldman and J.M. Schwartz: “Case report: aplastic anemia associated with antithyroid drugs”, Am. J. Med. Sci., Vol. 301, (1991), pp. 190–194 http://dx.doi.org/10.1097/00000441-199103000-00008[Crossref]
• [2] G. Birchell and T. Cheetham: “Juvenile thyrotoxicosis; can we do better?”, Arch. Dis. Child., Vol. 89(8), (2004), pp. 745–750
• [3] U. Srinivas, S. Stanaway, R. Worth and D. Ewins: “Delayed carbimazole induced agranulocytosis precipitating thyroid crisis”, Endocrine abstracts, Vol. 5, (2003), P27.
• [4] F. Joseph, N. Younis and D. Bowen Jones: “Treatment of carbimazole-induced agranulocytosis and sepsis with granulocyte colony stimulating factor”, Int. J. Clin. Prac., Vol. 57(2), (2003), pp.145–146
• [5] G. Wilcox, R. Wong, P.J. Elliott, D.J. Topliss and J.R. Sockigt: “Recovery from Carbimazole-Induced Aplastic Anaemia”, Int. J. Endocrinol. Metab., Vol. 1, (2003), pp. 41–43
• [6] D. Usha, D.M. Thatte and S.A. Dahanukar: “Therapeutic potential of the haematopoietic growth factors”, J. Postgrad. Med., Vol. 40(4), (1994), pp. 210–15
• [7] A. Oyama, K. Ota, S. Asano, F. Takaku, T. Miyazaki, Y. Uzuka, M. Omine, S. Furusawa, K. Hirashima, K. Sanpi et al: “Clinical effect of recombinant human G-CSF on neutropenia induced by chemotherapy for Non Hodgkin’s lymphoma”, Nippon Gan. Chiryo. Gakkai. Shi., Vol. 25(8), (1990), pp. 1619–1634.

Identifiers

DOI

10.2478/s11536-006-0036-5